IMAB Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 jun 2024 @ 20:48):
Our systems believe the stock currently is overvalued by -0.06% compare to its pairs and should correct downwards.

Stats
Dagens volum	134 296
Gjennomsnittsvolum	225 654
Markedsverdi	132.48M
EPS	CNY-1.240 ( Q4 \| 2024-04-30 )
Neste inntjeningsdato	( CNY0 ) 2024-08-15
Last Dividend	CNY0 ( N/A )
Next Dividend	CNY0 ( N/A )
P/E	-0.710 (Sector) 42.63 (Industry) 24.32
ATR14	CNY0.0100 (0.58%)

AADI -6.47%

ABCL 2.38%

ABCM 0.04%

ABEO -3.08%

ABIO -1.68%

ABOS 5.14%

ABSI 4.93%

ABUS -0.66%

ABVX -1.88%

ACAD 0.10%

ACER -17.95%

ACET -8.50%

ACGN 1.29%

ACHL -2.48%

ACHV 3.66%

ACIU -1.50%

ACLX 0.37%

ACRV -5.61%

ACST -4.89%

ACXP 3.92%

ADAG 6.07%

ADAP -3.28%

ADGI 0.87%

ADIL 0.88%

ADMA -1.77%

ADPT 0.89%

ADTX -2.78%

ADVM 1.01%

ADXN -1.60%

AEON -2.80%

AEZS -2.49%

AFMD -1.92%

AGEN -3.30%

AGIO -2.01%

AGLE 6.66%

AGTC 0.00%

AIKI 0.85%

AIMDW -13.88%

AKBA 5.29%

AKRO -2.89%

AKTX -2.38%

AKUS 0.00%

ALBO 0.00%

ALDX -1.99%

ALEC 0.00%

ALGS 1.32%

ALKS 1.61%

ALLK -11.44%

ALLO -3.96%

ALLR -2.50%

ALNA 3.16%

ALNY 2.93%

ALPN 0.02%

ALPX 0.00%

ALRN -2.24%

ALT -13.70%

ALVR -0.70%

ALXN 0.00%

ALXO -13.62%

ALZN 4.02%

AMRN -1.86%

AMTI -3.13%

ANAB 1.47%

ANEB 6.06%

ANGN 0.00%

ANIX -3.04%

ANL -0.14%

ANNX 2.40%

ANPC -3.15%

APGE 0.40%

APGN 8.48%

APGNW 30.65%

APLM -5.90%

APLS 0.89%

APLT -0.68%

APM 1.26%

APOP 0.38%

APRE 0.84%

APTO 4.82%

APTX 3.17%

APVO 0.93%

ARAV -13.39%

ARCT -5.22%

ARDS -12.13%

ARDX 1.25%

ARGX -0.50%

ARNA 0.00%

ARPO -0.90%

ARQT -2.55%

ARTL -2.50%

ARTLW 0.00%

ARVN 7.32%

ARWR -1.56%

ASLN -3.24%

ASMB -4.22%

ASND -2.22%

ATAI -3.33%

ATHA 6.86%

ATHE 0.56%

ATHX -33.50%

ATNF 0.99%

ATOS 4.85%

ATRA -3.34%

ATXI 2.70%

ATXS -0.28%

AUPH -0.99%

AURA 4.55%

AUTL -3.07%

AVBP -3.35%

AVEO 0.00%

AVIR -2.33%

AVRO -1.41%

AVTE 0.34%

AVTX -3.74%

AVXL -4.82%

AXLA 0.00%

AXSM -1.18%

AYLA 0.00%

AZRX 2.07%

BBI 2.17%

BBIO 2.35%

BCAB -1.63%

BCDA -3.15%

BCDAW -41.77%

BCEL 0.00%

BCLI 4.21%

BCRX 1.98%

BCTX 8.16%

BCTXW 13.02%

BCYC 0.90%

BDRX -4.09%

BDTX 0.21%

BEAM 2.52%

BFRA -2.91%

BGNE -2.01%

BIOR -5.27%

BIVI 3.03%

BLCM -6.68%

BLI -5.88%

BLPH 0.00%

BLRX -3.47%

BLTE -1.03%

BLU 0.03%

BLUE -1.88%

BMEA -13.03%

BMRN 0.51%

BNOX 6.15%

BNTC -1.69%

BNTX -1.59%

BOLD -8.35%

BOLT -0.09%

BPMC -1.36%

BPTH -1.90%

BPTS -13.47%

BRNS -0.37%

BRTX -6.10%

BTAI 16.04%

BTTX 20.00%

BTX 0.05%

BVXV 0.74%

BXRX 7.39%

BYSI 2.97%

CABA 0.97%

CADL 0.71%

CALA 0.00%

CALC -3.74%

CALT -1.59%

CAPR -1.08%

CARA -3.26%

CARM 6.96%

CASI -1.65%

CATB -6.97%

CBAY 0.03%

CBIO -2.65%

CBLI -7.31%

CBUS 0.56%

CCCC -2.23%

CCXI 0.00%

CDAK 0.00%

CDIO -5.08%

CDIOW 24.00%

CDMO -1.55%

CDMOP 0.04%

CDT -0.81%

CDTTW -39.60%

CDTX -4.77%

CDXC 7.17%

CDXS 9.31%

CELC -3.09%

CELU 2.67%

CELUW 11.80%

CERC -1.68%

CERE -1.90%

CERO -7.30%

CEROW -10.18%

CFRX -27.95%

CGEM 0.18%

CGEN -3.31%

CGON -1.39%

CGTX -4.35%

CHMA -6.00%

CHRS 4.11%

CINC 0.00%

CING -2.56%

CINGW 34.95%

CKPT -1.44%

CLBS -16.75%

CLDX -0.88%

CLGN 0.70%

CLLS -3.63%

CLNN -2.67%

CLNNW 0.00%

CLRB 7.38%

CLSD -2.40%

CLSN -0.68%

CLVS 0.00%

CMMB -3.89%

CMND 5.60%

CMPI 0.00%

CMPX -0.94%

CMRA 0.00%

CMRAW 33.33%

CMRX -4.42%

CNCE 0.00%

CNSP -36.27%

CNST 0.00%

CNTA -0.11%

CNTB -0.75%

CNTX -4.79%

COCP -2.00%

COEPW 32.45%

COGT -2.16%

CORT 2.60%

COYA -0.65%

CPRX -1.91%

CRBP -0.24%

CRBU -6.82%

CRDF 1.55%

CRGX -0.03%

CRIS -3.19%

CRNX -6.05%

CRSP -0.24%

CRTX 2.63%

CRVO -2.20%

CRVS 0.56%

CSBR 0.11%

CTCX -1.59%

CTIC 0.06%

CTMX -2.90%

CTNM 1.98%

CTXR -1.47%

CUE -1.74%

CVAC -8.05%

CVKD -2.34%

CWBR 2.80%

CYAD -12.96%

CYCC 8.49%

CYCCP 5.28%

CYCN 7.81%

CYT -2.27%

CYTK -2.48%

CYTO -0.89%

DARE 3.54%

DAWN -0.75%

DBTX -0.81%

DBVT 4.17%

DFFN 10.28%

DICE 0.06%

DMAC 28.76%

DNLI -1.70%

DNTH -4.26%

DOMH 1.59%

DRMA -2.57%

DRMAW -1.25%

DRNA 0.00%

DRTS 0.46%

DRTSW 0.00%

DRUG 1.43%

DSGN -2.42%

DTIL -0.24%

DYAI 9.68%

EARS -1.77%

EDIT -2.62%

EDSA 4.09%

EFTR 4.43%

EFTRW -53.85%

EIGR -9.21%

ELAB -3.01%

ELDN 8.37%

ELEV -1.24%

ELOX 10.77%

ELTX -5.15%

ELVN -1.91%

ELYM 4.60%

ENGN 0.86%

ENGNW 0.00%

ENLV 0.00%

ENOB 1.79%

ENSC 6.53%

ENTA 0.41%

ENTO -4.97%

ENTX -0.53%

ENVB 8.03%

EPIX -0.73%

EPRX -1.92%

EPZM 0.00%

EQ -0.90%

EQRX -2.09%

EQRXW 0.00%

ERAS -0.48%

ERNA -2.78%

ERYP 1.30%

ESLA 4.30%

ESLAW 16.64%

ETNB -3.56%

ETON 3.35%

ETTX 0.00%

EVAX -0.71%

EVGN 4.76%

EVLO 0.00%

EWTX -1.74%

EXAI 0.00%

EXEL 0.47%

EYEG -0.69%

EYEN 0.68%

EYPT 1.69%

FATE -11.42%

FBIO 0.86%

FBIOP 0.87%

FBLG -6.80%

FBRX -0.02%

FDMT -4.68%

FENC -2.26%

FGEN -9.83%

FHTX 8.02%

FIXX 0.77%

FMTX 0.00%

FNCH 0.00%

FOLD -1.37%

FREQ 4.76%

FRLN 0.15%

FRTX 0.00%

FSTX 0.00%

FTRE 1.02%

FULC 1.84%

FUSN 0.00%

FWBI 4.59%

FWP 0.00%

GALT -0.43%

GANX -2.31%

GBIO -2.12%

GBT 0.01%

GDTC 0.50%

GERN -3.10%

GHRS -3.72%

GLMD -4.09%

GLPG -1.56%

GLSI 5.01%

GLTO -3.31%

GLUE -3.43%

GLYC -11.41%

GMAB -0.25%

GMDA -18.25%

GMTX 0.00%

GNCA -85.71%

GNFT -2.60%

GNLX -4.42%

GNPX -2.86%

GNTA 3.94%

GOSS -10.64%

GOVX -2.67%

GOVXW 10.89%

GPCR -6.31%

GRAY -10.80%

GRCL 0.05%

GRNA -0.03%

GRNAW 8.91%

GRPH -2.75%

GRTS -0.36%

GRTX -1.66%

GTHX 1.14%

GUTS 2.77%

GXGXW 41.67%

GYRE -4.54%

HALO -1.70%

HARP 0.09%

HCWB -6.13%

HEPA -3.62%

HGEN -84.62%

HILS 5.66%

HLVX -1.34%

HOOK 0.89%

HOTH -1.11%

HOWL 2.99%

HRMY 4.82%

HRTX 9.02%

HSTO 0.00%

HUMA 1.42%

HUMAW -6.26%

IBRX -5.30%

ICCC -4.42%

ICPT 0.21%

ICU 15.41%

ICUCW 20.20%

ICVX -0.91%

IDRA -23.04%

IDYA -2.88%

IFRX -2.77%

IGMS -1.32%

IKNA -0.30%

IKT -9.86%

IMAB 0.03%

IMCR -3.16%

IMGN 0.02%

IMGO 0.00%

IMMP 4.37%

IMMX -5.60%

IMNM 4.51%

IMNN 0.27%

IMPL -27.27%

IMRA 15.96%

IMRN -0.40%

IMRX -3.15%

IMTX -0.92%

IMTXW 6.00%

IMUX 1.85%

IMV 0.00%

IMVT -3.44%

INAB -1.66%

INBX -2.05%

INCY -2.25%

INDP 8.49%

INFI -52.38%

INKT 2.10%

INM 3.22%

INMB 4.18%

INO 2.21%

INSM -0.98%

INTS -1.96%

INVA 0.19%

INZY 2.29%

IOBT -11.02%

IONS 1.43%

IOVA -2.54%

IPA 3.00%

IPHA 3.05%

IPSC -2.34%

IRON -2.51%

ISEE 0.38%

ITOS 0.89%

ITRM 2.33%

IVA 6.96%

IVVD -0.41%

JAGX 1.31%

JANX -4.24%

JAZZ -0.88%

JNCE 0.00%

JSPR -1.90%

JSPRW 20.88%

JUNS 0.00%

JUNSW 0.00%

KA -2.45%

KALV -3.90%

KDNY 0.22%

KMPH -0.34%

KNSA -2.06%

KNTE -0.38%

KOD -7.51%

KPRX -4.80%

KPTI -8.22%

KRBP -10.00%

KRON 1.16%

KROS -0.26%

KRRO -2.26%

KRTX 0.03%

KRYS 0.44%

KTRA 10.61%

KTTA -0.65%

KTTAW 0.92%

KURA 0.29%

KYMR -2.87%

KYTX -3.23%

KZIA 4.41%

KZR -0.12%

LABP 0.57%

LBPH -0.20%

LBPS 0.00%

LBPSW 14.81%

LEGN 1.06%

LENZ -2.54%

LEXX -1.16%

LEXXW -14.63%

LGND -1.29%

LGNDV 0.00%

LGVN -9.28%

LIAN -8.28%

LIFE 2.70%

LIPO -5.10%

LIXT -9.76%

LIXTW 46.21%

LJPC -0.32%

LMNL 0.12%

LOGC 1.48%

LPCN -3.68%

LPTX -2.75%

LQDA 0.49%

LRMR 0.78%

LSTA -1.68%

LTRN 5.02%

LUMO 1.79%

LVTX -2.58%

LXEO -8.39%

LXRX -1.76%

LYEL -35.54%

LYRA 1.94%

MACK 0.10%

MBIO -11.30%

MBRX -1.43%

MCRB 3.05%

MDGL -2.08%

MDNA -13.16%

MDWD 3.56%

MDXG -2.21%

MEIP 0.00%

MESO -1.55%

MGNX -4.31%

MGTA -7.74%

MGTX -0.83%

MGX 2.41%

MIRM 0.42%

MIRO 0.59%

MIST 2.66%

MITO 0.00%

MLEC -7.68%

MLECW 2.31%

MLND -5.36%

MLTX 0.11%

MLYS -5.86%

MNKD -0.38%

MNMD 4.67%

MNOV 2.11%

MNPR -8.56%

MOLN 2.20%

MOR 0.45%

MORF -3.10%

MREO -2.57%

MRKR -0.43%

MRNA -8.98%

MRNS -5.51%

MRSN -2.86%

MRTX -0.17%

MRUS -0.81%

MRVI -0.66%

MTCR -1.29%

MTEM 6.93%

MTP -18.50%

MURA -4.33%

MYMD 1.08%

NAMS -0.65%

NAMSW -0.21%

NAUT 1.33%

NBRV 0.71%

NBSE -1.56%

NBTX 12.09%

NCNA 0.00%

NERV -1.58%

NEXI -0.74%

NGM -1.28%

NGNE 3.70%

NKGN 10.09%

NKGNW 8.00%

NKTR 4.69%

NKTX -4.08%

NLSP 3.53%

NLSPW 26.67%

NMRA -0.97%

NMTR -42.97%

NOVN -24.84%

NRBO 16.59%

NRIX -0.48%

NRSN -4.82%

NRSNW 0.00%

NRXP -7.81%

NRXPW 18.33%

NRXS -1.20%

NTBL 2.63%

NTEC -12.45%

NTHI 0.00%

NTLA -5.17%

NTRBW -31.07%

NUVL -1.00%

NVAX -6.99%

NVCT -7.75%

NVIV -34.28%

NXTC -3.53%

NYMX -0.05%

OABI 3.17%

OABIW -10.06%

OBIO -1.17%

OBSV 0.00%

OCEA -2.11%

OCGN 8.91%

OCS -1.00%

OCUL 0.91%

OCUP 0.65%

ODT -4.27%

OKYO 2.15%

OLMA -5.03%

OMER -2.83%

OMGA 0.42%

ONCO 5.89%

ONCR -3.08%

ONCS 31.87%

ONCT -2.35%

ONCY 2.94%

ONTX -0.47%

ONVO 0.29%

OPNT 0.00%

OPT 2.06%

ORGS 1.19%

ORIC -1.34%

ORMP 18.30%

ORPH 0.00%

ORTX 0.30%

OSMT -1.77%

OTIC -92.64%

OTLK -1.18%

OVID 0.00%

OYST 0.00%

PALI -0.22%

PASG 2.63%

PBLA -7.50%

PBM -4.70%

PBYI 2.87%

PCSA -1.93%

PCVX 0.05%

PDSB -6.17%

PEPG 1.67%

PGEN -6.04%

PHAR 2.19%

PHAS 0.00%

PHAT -0.48%

PHIO -3.58%

PHIOW 36.47%

PHVS -5.83%

PHXM -5.20%

PIRS 0.58%

PKBO 0.00%

PKBOW 999 900.00%

PLRX -1.83%

PLUR 7.39%

PMN -5.55%

PMVP -2.38%

PNT 0.16%

PPBT -6.43%

PRAX 7.24%

PRDS 0.93%

PRLD -2.64%

PROG -3.47%

PROK -0.45%

PRQR 0.60%

PRTA -2.60%

PRTC 0.62%

PRTG 1.00%

PRTK 1.83%

PRVB 0.00%

PSTI -2.91%

PSTV -14.04%

PSTX -2.71%

PTCT -0.48%

PTE -0.82%

PTGX -0.82%

PTIXW -48.41%

PULM 1.53%

PXMD 4.76%

PYPD 1.71%

PYXS 4.41%

QLGN -7.18%

QNCX 5.70%

QNRX -0.49%

QSI -36.12%

QSIAW -3.13%

QTTB 1.82%

QURE -0.34%

RAIN -1.63%

RANI 4.81%

RAPT -1.56%

RARE 2.15%

RCKT -9.06%

REGN -0.41%

RENB -3.42%

REPL -0.96%

RETA 0.02%

REUN -0.89%

REVB -1.40%

REVBU 3.46%

REVBW 5.00%

RGLS -5.32%

RGNX -6.33%

RIGL -6.03%

RLAY -4.45%

RLMD 0.00%

RLYB -4.36%

RNA 1.18%

RNAC -4.62%

RNAZ 0.00%

RNXT 1.80%

ROIV -1.66%

ROIVW 4.56%

RPHM -0.93%

RPRX -0.67%

RPTX -0.59%

RUBY 2.70%

RVLP -32.05%

RVMD -0.39%

RVMDW -29.90%

RVNC -0.43%

RVPH -0.80%

RVPHW -5.28%

RXDX 0.09%

RXRX -5.97%

RYTM -5.80%

RYZB 0.02%

RZLT 2.71%

SABS -1.37%

SABSW -11.81%

SAGE 0.55%

SANA -2.77%

SAVA -1.55%

SAVAW 0.00%

SBBP 1.52%

SBTX 1.03%

SCNI 2.65%

SCPH 10.10%

SCPS 0.00%

SEEL -4.85%

SEER 0.00%

SELB -8.00%

SESN 7.29%

SGEN -0.07%

SGMO -1.39%

SGMT -4.95%

SGTX -2.56%

SIOX 22.63%

SLDB -3.61%

SLGL 5.23%

SLN -7.29%

SLNO 0.44%

SLRX 1.23%

SLS -2.58%

SMMT -3.00%

SNDX 3.10%

SNGX -0.38%

SNPX -2.56%

SONN -1.08%

SPPI -0.49%

SPRB -1.38%

SPRC -4.25%

SPRO 0.75%

SRNE 0.00%

SRPT -1.19%

SRRA 0.00%

SRRK -1.36%

SRZN -2.45%

STAB 0.00%

STOK -6.81%

STRO -1.34%

STSA 0.00%

STTK 6.33%

SURF -0.93%

SVRA -1.42%

SWTX 0.14%

SYBX 1.29%

SYRS -2.16%

TALS -0.73%

TARA -7.38%

TARS -1.90%

TBPH 0.77%

TCBP 5.56%

TCDA 0.00%

TCON 0.00%

TCRR 0.00%

TCRT -1.75%

TCRX 4.52%

TECH -0.75%

TENX -0.32%

TERN -8.83%

TFFP -7.61%

TGTX -7.04%

THRX 0.12%

TIL -1.09%

TLC 0.00%

TLSA -7.23%

TNGX -3.24%

TNXP -5.60%

TNYA -4.55%

TPST 7.05%

TRDA -4.67%

TRVI 2.68%

TRVN 3.18%

TSHA -18.86%

TSVT -4.26%

TTNP -6.05%

TVTX 3.08%

TYRA -6.95%

UBX -2.55%

UNCY -3.99%

URGN 2.64%

UTHR -0.06%

VACC 11.36%

VALN -6.70%

VAXX 118.69%

VBIV 0.93%

VBLT -8.77%

VCEL 1.04%

VCNX 9.03%

VCYT -0.70%

VERA -5.62%

VERU 1.33%

VERV -2.29%

VIGL -1.58%

VINC 2.99%

VIR -0.49%

VIRI -5.41%

VIRX 3.98%

VKTX -1.53%

VLON -13.04%

VNDA -3.91%

VOR -6.05%

VRCA 0.36%

VRDN -3.29%

VRNA -1.26%

VRPX 1.02%

VRTX 0.10%

VSTM 3.91%

VTGN -1.66%

VTVT 0.39%

VTYX -2.30%

VXRT -2.30%

VYGR -0.77%

VYNE -5.20%

VYNT 7.78%

WINT -0.60%

WVE -8.18%

XBIO 1.03%

XBIT 7.50%

XCUR 3.77%

XENE -1.97%

XERS 5.24%

XFOR 5.73%

XLO 4.42%

XLRN 0.00%

XNCR 0.41%

XOMA -10.03%

XOMAO -0.45%

XOMAP -0.82%

XRTX -7.96%

YMAB -1.06%

ZGNX 0.00%

ZIOP -0.88%

ZLAB -3.67%

ZNTL -1.79%

ZSAN 0.00%

Korrelasjon (AI algo v.1.1b): Overvalued: -0.06% CNY1.721 paired level. (Algoen sporer endringene til de mest korrelerte aksjene i sanntid og gir umiddelbar oppdatering)

Volum Korrelasjon

Lang: 0.03 (neutral)

Kort: 1.00 (very strong)

Signal:(46.032) Expect same movement, but be aware

I-Mab Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

I-Mab Korrelasjon - Valuta/Råvare

-0.24
( neutral )

-0.54
( weak negative )

0.00
( neutral )

-0.42
( neutral )

I-Mab Økonomi

Annual	2023
Omsetning:	CNY27.64M
Bruttogevinst:	CNY27.64M (100.00 %)
EPS:	CNY-16.53

FY	2023
Omsetning:	CNY27.64M
Bruttogevinst:	CNY27.64M (100.00 %)
EPS:	CNY-16.53

FY	2022
Omsetning:	CNY-221.56M
Bruttogevinst:	CNY-248.80M (112.29 %)
EPS:	CNY-31.75

FY	2021
Omsetning:	CNY88.03M
Bruttogevinst:	CNY41.59M (47.25 %)
EPS:	CNY-29.19

Financial Reports:

No articles found.

I-Mab Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

I-Mab

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; TJ107, a recombinant human IL-7, which is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat lymphopenia and cancer immunotherapy; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody for inflammation and CRS-related therapies; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers, as well as TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for solid tumors and TJ-C64B, a tumor-dependent T-cell engager for ovarian and other cancers. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.